Open Access

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: the next chapter in CVD prevention

Event: ESC CONGRESS 2017
Topic: Atherosclerosis
Session type: Satellite Symposium
Sponsored by Amgen GmbH
Date: 27 August 2017
Time: 18:30 - 19:15

Congress Session

3 presentations in this session

PCSK9 inhibitors: the story continues.

Speaker: Professor J. Chapman (Paris, FR)
Thumbnail

Challenging the data.

Speaker: Professor J. Chapman (Paris, FR)
Speaker: Professor P. Sever (London, GB)
Thumbnail

PCSK9 inhibitors: more volumes to come?

Speaker: Professor J. Chapman (Paris, FR)
Thumbnail

4 speakers from this session

Professor John Chapman

Sorbonne University, Paris (France)
15 presentations
0 follower

Professor John Chapman

Sorbonne University, Paris (France)
15 presentations
0 follower

Professor Peter S Sever

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)
4 presentations
0 follower

Professor John Chapman

Sorbonne University, Paris (France)
15 presentations
0 follower

This platform is supported by

logo Novo Nordisk